MedTrace Logo

Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients

NCT00884169 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2010-11-03

No results posted yet for this study

Summary

This study is to investigate the efficacy and safety of M518101 in male and female plaque psoriasis patients with refractory plaques.

Conditions

Interventions

DRUG

M518101

Proper quantity twice a day

DRUG

placebo

Proper quantity twice a day

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Completion
2009-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884169 on ClinicalTrials.gov